赛默飞世尔（TMO）发布了2026年的业绩指引，预计收入同比增长3.9%至5.9%，调整后每股收益增长5.9%至8.4%，并重申长期有机收入增长目标为3%-6%。公司在2025年完成了对Solventum过滤与分离业务及赛诺菲新泽西州无菌灌装设施的收购，并宣布拟以89亿美元收购临床数据服务商Clario，以加强生物生产与药品本土化能力。生命科学解决方案板块成为核心增长引擎，利润同比增长7.6%，而...
Source Link赛默飞世尔（TMO）发布了2026年的业绩指引，预计收入同比增长3.9%至5.9%，调整后每股收益增长5.9%至8.4%，并重申长期有机收入增长目标为3%-6%。公司在2025年完成了对Solventum过滤与分离业务及赛诺菲新泽西州无菌灌装设施的收购，并宣布拟以89亿美元收购临床数据服务商Clario，以加强生物生产与药品本土化能力。生命科学解决方案板块成为核心增长引擎，利润同比增长7.6%，而...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.